Abstract: Complex diseases are commonly believed to be caused by the breakdown of several correlated genes rather than individual genes. The availability of genome-wide data of high-throughput experiments provides us with new opportunity to explore this hypothesis by analysing the disease-related biomolecular networks, which are expected to bridge genotypes and disease phenotypes and further reveal the biological mechanisms of complex diseases. In this study, the authors review the existing network biology efforts to study complex diseases, such as breast cancer, diabetes and Alzheimer's disease, using high-throughput data and computational tools. Specifically, the authors categorise these existing methods into several classes based on the research topics, that is, disease genes, dysfunctional pathways, network signatures and drug-target networks. The authors also summarise the pros and cons of those methods from both computation and application perspectives, and further discuss research trends and future topics of this promising field.
Introduction
Network-based systems biology or network biology, a booming area studying various biomolecular networks, is a multidisciplinary intersection of mathematics, computer science and biology [1 -3] . In the past years, rapidly accumulated high-throughput data have driven the integrative study from describing complex phenomena to understanding essential design principles, from studying individual components to understanding functional networks for biomolecular systems, such as cells, tissues, organs and even the entire organisms [4, 5] . Network provides a quantifiable alternative to model the complex relationship between these objectives, which has fundamentally inspired a novel view of cell biology [2, 3] . In contrast to the study on individual molecules, network biology aims to investigate how cellular systems facilitate biological phenotypes arising in the form of networks among genes, proteins and metabolites [2] . The rapid advances in network biology have effectively provided valuable frameworks and pipelines to analyse highthroughput data, significantly altered our understanding of biological systems, and embedded in important applications in practical medicine [1 -3] . In particular, the occurrence and development of a complex disease, one of the most important biological phenotypes, can be viewed as the spatio-temporal change or dynamics of the respective biomolecular network. Therefore the study based on biomolecular networks offers a new conceptual framework that could potentially revolutionise our view on biology and pathologies. Actually, the emergence of genomic, transcriptomic, proteomic and metabolomic resources and network-based technologies are revolutionising biomedicine research, by providing a transition opportunity of complex diseases study from the traditional genetic studies to a new paradigm of systems biology. Towards this grand roadmap, applications of biomolecular networks to study complex diseases provide very effective ways to meet these technological, biological and algorithmic challenges [6, 7] . The difficulties on this area arise from the following three aspects. First, the occurrence and development of the complex diseases involve multiple genetic factors, epigenetic factors (e.g. environmental factors) and their interactions. Second, different kinds of cells or tissues are involved in the development and progression of diseases. For example, the brain, pancreas, liver, skeletal muscle and adipose tissue are all involved in the type-2 diabetes [8] . Third, the molecular defects of a complex disease disrupt the normal behaviours of the complex molecular networks of genes and proteins, which also add an additional difficulty.
We note that the complex diseases, such as cancer, diabetes and Alzheimer's disease (AD), have been extensively studied for a long time. The classical biomedicine based on molecular biology, cell biology, genetics and other experimental biology, has made significant progress in elucidating the mechanism of complex diseases in general. However, the biomedicine researchers still face the great challenges against the complex diseases since the methodology of the classical experimental biology is mainly based on studying individual genes and proteins and generally treats an organism as a linear system, which is too simplified and far from enough to understand the occurrence and development of complex diseases [9] . In contrast, systems biology, in particular network-based systems biology, provides us new ways to understand the non-linear interactions of multiple biomolecular components and to characterise the phenotype change by analysing the dynamical behaviours of biological networks. It may shed light on multifactorial diseases with complex aetiologies to identify the biological pathways or networks that connect the differing elements of a system and examine how they evolve with temporal and environmental changes [2] .
In this paper, we provide a brief review on network-based studies of complex diseases. Firstly, we categorise the biomolecular networks into different levels via the available genome-wide data and describe the relationship between networks and diseases. Then we focus on several popular topics regarding the analysis on complex diseases from perspectives of network biology, such as identifying candidate disease genes, disease-responsive dysfunctional pathways and network biomarkers of disease signatures. In addition, the studies on the disease associations are summaried. We also provide a brief review on the pharmacology researches of drug combination and drug target prediction by network-based methods. Further research trends and future topics are also discussed from the computation and application perspectives. Finally, we make several general remarks on the study of complex diseases in the network framework to conclude this paper.
Biomolecular networks for complex diseases
Genes, RNAs, proteins and metabolites are known as biological molecules. Cells comprise thousands of such molecular entities interacting in very complex ways. Networks present a powerful framework to represent these complicated relations and interactions, which are responsible for various cellular functions with the collaborative effects of those individual nodes of molecules. Thus in such a sense, cellular processes and functions are actually achieved by biomolecular networks [1] . A living organism can then be regarded as a huge non-linear biochemical reaction system, which can be simplified and represented as various types of biomolecular networks [2] .
In this framework, complex diseases are believed to be dysfunctions of such networks rather than single components or molecules [10] . The biomolecular networks indispensably exist in cellular systems and play fundamental and principal roles in giving rise to life and maintaining the homoeostasis in living organisms. Specifically to complex diseases, the available highthroughput data provide new opportunity to investigate the essential mechanisms by biomolecular networks, in which each node is a biological molecule, and each edge represents the dysfunction interaction or association of a pair of molecules related to disease. Fig. 1 shows how the associated networks can bridge the genotypes and phenotypes of complex diseases.
Traditionally, disease study focused on individual genes or proteins related to certain phenotype. Network-based approach provides new alternatives for studying complex diseases by investigating groups of related molecules simultaneously. Fig. 1a shows individual components in a cellular system. Their corresponding biomolecular networks at different levels form a hierarchical structure as shown in Fig. 1b . At the genomic level, transcription factors (TFs) regulate the gene activities of synthesising mRNAs. Although these TFs are themselves products of genes, the effects of regulating gene expression each other will be parts of a transcription regulatory network or gene regulatory network. Similarly, at the proteomic level, proteins interact with other proteins to form protein complexes and pathways to participate in various biological processes. Such associations between protein molecules are called protein-protein interactions (PPIs), which lead to a PPI network. The biochemical reactions in cellular metabolism can likewise be integrated into a metabolic network whose fluxes are regulated by enzymes that catalyse the reactions. In many cases, these interactions at different levels are integrated into signalling networks [2] . Moreover, we often represent the interested biological entities and their relationships by functional association networks. The various definitions of nodes and their indications provide substantial network resources to study complex diseases.
In a biological system with disease, the dysfunctional processes are underlying in these various networks. The z-axis Fig. 1c indicates the available omics data and the corresponding networks at different levels. The y-axis in Fig. 1c reveals the main research 'objects' in a single network, where a network is formed conceptually from individual molecules, to pairwise interactions, to local structures (such as network motifs [11, 12] , modules, communities [13] and pathways) and eventually to a global network. Clearly, basic units or components in a network are individual molecules, which affect each other by their local or pairwise interactions. A chain or cascade of those local interactions is a linear pathway or local structure which transforms local perturbations into a dysfunctional response. All the linear pathways or local structures are assembled into a global molecular network, which eventually generates global behaviours and holds responsibility for the complicated life in a living organism [2, 3] . There are a broad research topics existing in network-based systems biology, shown in the x-axis in Fig. 1c , including the network reconstruction, network feature identification in multilevel networks, functional local structure detection, network analysis and network dynamics in different biological processes and different timescales. Modelling the living systems by networks and analysing complex diseases by networks enable us to address the complex dysfunctional processes and to provide valuable insights to decipher the cellular phenotypes and behaviours [2, 3] .
Given a network or graph G ¼ (V, E), where V is the node set and E is the edge set, we can describe a network in a mathematical manner based on the graph theory [14] . Network concepts are able to provide important biological insights for complex diseases. For example, a hub (a node with a high degree) in the network may correspond to a network component with central biological roles. A number of network definitions have been introduced to describe the complex relationship of these nodes in the network [15, 16] . Topological analysis is the first step towards understanding biological functions and design principles of a network [17, 18] . The topology features of nodes (i.e. individual molecules) in a network, edges (i.e. interacting pairs), network motifs and modules (i.e. local structures) as well as global network structures present valuable information to identify diseaserelated genes, dysfunctional pathways, disease-responsive subnetworks, as well as the disease relationships. The network also benefits the design of drug targets and drug combination for the therapy of complex diseases.
Analysis of complex diseases by networks

Disease gene prioritisation
Identification of candidate genes associated with physiological disorder is a fundamental task to analyse a complex disease. Traditional gene mapping approaches, such as gene linkage analysis or association studies, which utilise only sequence information, are time-consuming and expensive to inspect of the large number of genes in the resultant region [19] , and have limited efforts to localise the casual genes in the genome [20, 21] . The availability of high-throughput molecular interaction network provides valuable resources for disease gene prediction. The advantage is that a biomolecular network is able to model the complex relationship of disease genes in the cellular processes, and genes related to a specific disease phenotype also tend to be closely located in the network. A general network-based scheme of prioritising or predicting disease genes is summarised in Fig. 2 . First, the candidate genes within a linkage interval are mapped to a human gene/protein/functional/integrated network. Second, some of the known disease genes are highlighted as seed genes in the network. By combining with the prior knowledge about the seed genes and the distance between the known disease genes and a candidate gene in the network, we can develop a scoring scheme to evaluate the possibility of the candidate to be a disease gene. Finally, all the candidate genes are ranked by their associations with the disease.
A number of computational methods have been proposed to address this problem, and typical network-based methods for ranking or predicting disease genes are listed in Table 1 . The topological properties of the network are often investigated in the prediction scheme. For instance, the shortest path length between a candidate gene and the known disease genes is a widely used measure of their association with the disease. Molecular triangulation [22] is a method based on this scoring scheme. It firstly constructed a human protein interaction network related to AD by literature mining techniques. After assigning a primary-evidence value to a subset of disorder genes as seed nodes in the network, it computes a secondaryevidence value to combine the multiple primary-evidence values by
where E(u) is the secondary evidence for node u, E p (v) is the primary evidence for seed node v and B is the set of all seed nodes of known disease genes. With the analogy of electric potential, the secondary-evidence value will decay with the distance from the seed gene. Then the shortest path lengths d uv between node u to the seed node v are calculated and Fig. 2 Framework to prioritise candidate disease genes the distance-dependent decay function f is defined as
The score is transformed to a statistical significance p-value to measure the dysfunctional possibility related to AD. Top ranking procedure prioritises disease-related candidate genes. The method performed well based on the basic assumption that common phenotypes are associated with protein dysfunctions in the same network. The network presents an effective framework to combine the genetics with molecular network and pathway information to identify disease-related gene variants [22] .
George et al. [25] proposed another candidate disease gene prediction method by common pathway scanning. It utilised network data derived from protein interaction and pathway databases to identify relationships among genes. They also used the shortest path length scoring scheme and compared/ combined their method with domain-dependent sequence similarity approach. On the other hand, Ma et al. [27] developed a system for gene prioritisation associated with AD by combining gene expression and PPI network using Markov random field theory. They also compared the scoring schemes by the nearest neighbour and shortest path length. To investigate the global distance measure between candidate genes and the network information, Kohler et al. [29] proposed a differential kernel scheme to grasp the integrated contribution of other genes. Franke et al. [24] combined gene ontology (GO), gene co-expression, and protein interactions, by the Bayesian method to build a functional gene network and tested the prediction performances with different combinations by a Gaussian kernel scoring function in 96 heritable disorders. Morrison et al. [23] designed a gene prioritisation method to analyse microarray data based on the PageRank searching algorithm. They used GO network, gene co-expression network and synthetic network for the task of prioritising the 'importance' of genes in a microarray experiment. Lage et al. [28] performed a systematic analysis of human protein complexes comprising gene products implicated in different categories of human diseases by creating a phenomeinteractome network. They collected the disease protein complexes and defined the phenotype similarity scores. The disease genes were ranked and tested by a Bayesian predictor. Wu et al. [30] also provided a method called CIPHER to incorporate the phenotypic similarity information into the prediction systems. It combined the correlation information of different diseases in a protein interaction network and implemented various distance measures of nearest neighbour, shortest path and diffusion kernels to predict human disease genes. ENDEAVOUR [26] was proposed to integrate the information from various sources, such as the information from literatures, functional annotation, microarray expression, expressed sequence tags, protein domains, protein interactions, pathway membership, transcriptional motifs, sequence similarity and additional data sources, to identify the disease genes. It generated distinct prioritisation for these multiple heterogeneous data sources which were then fused together into a global ranking using order statistics. Jiang et al. [31] further found that using tissue-specific protein interaction network is helpful in predicting disease gene, and Chen et al. [32] demonstrated that considering the module structure in protein interaction network can improve the predictive power.
Dysfunctional pathway identification
It is well known that a complicated disease is not because of the breaking down of individual components but because of the local structures in the biomolecular network. Pathways represent molecular interactions and reaction networks for a key subsystem of the organisation that performs complex information processing and important tasks. Thus identifying an active pathway involved in a dysfunctional process is a central problem in complex disease study [33, 34] . In general, the set of interactions in the network activated under specific conditions may give hints to the dysfunctional process underlying the corresponding disease phenotypes. In this sense, active subnetworks or dysfunctional pathways of protein interactions associated with certain disease can help us discover potential network signatures or network biomarkers of the disease [35, 36] . Recently, microarray technologies and other highthroughput experiments provide dynamic information at specific time or condition. Some methods have been proposed to identify differential gene sets as differential pathways from gene expression data, such as gene set enrichment analysis (GSEA) [37] . It was effective to detect defined gene sets which are statistically significant in leukemia and lung cancer. Tian et al. [38] also provided a statistical enrichment analysis of gene sets to identify pathways in diabetes, inflammatory myopathies, and AD based on microarray data. However, microarray experiment is limited in its resolution to identify the dysfunctional interactions among these genes. PPIs provide a nonredundant line of evidence and can be combined with gene-expression information from microarray data to elucidate the interrelationships between genes and their participation in biological processes [7] . Based on GSEA, Liu et al. [8] developed a network-based analysis method, GNSE, with conventional gene set analysis to identify deregulated pathways in type-2 diabetes by combining gene expression and protein interaction information. Fig. 3 shows the general procedure to identify active pathways or functional modules in a weighted interaction network. Firstly, a background interaction network is reconstructed by integrating PPI data with other information. Then the background network is transformed into a weighted network by gene expression profiling and/ or other available data sources. Model and algorithm are then designed to identify putative responsive active pathways in the weighted network. This procedure also can be roughly described as the problem of identifying subnetworks with association to the disease [39] .
Several computational methods have been proposed to detect active pathways by integrating gene expression, protein interactions and other available information. Table 2 lists some of them. From the computational viewpoint, finding the maximal scoring connected subgraph from a weighted network is NP-hard [51] and thereby heuristic methods are in pressing need to tackle the problem because of its computational complexity [53] . jActiveModules [40] is one of the first method to investigate mechanism underlying the observed gene expression changes in the network framework. It extracts active subnetworks from PPIs and protein-DNA interactions. In this method, each gene or node in a network is firstly weighted by gene differential expression information. The p-value p i of the significance of expression for gene i is converted to a Zscore z i ¼ F
21
(1 2 p i ), where F 21 is the inverse normal cumulative distribution function [40] . Smaller p-values corresponds to larger Z-scores, which follow a standard normal distribution. For an entire subnetwork A of k genes, jActiveModules defines an aggregate score by summarising z i over all genes of A
According to the scoring system, subnetworks of all sizes are comparable. To determine the connection between expression and network topology, it calculates the expected score of randomly sample gene sets of size k by using a Monte Carlo approach. After deriving the score mean m k Fig. 3 Framework of identifying disease-responsive dysfunctional pathway and standard deviation s k for each k, the corrected subnetwork score is
The scoring scheme allows the method to score a given subnetwork. Importantly, it implements a simulated annealing algorithm to identify the highest-scoring subnetworks from the full weighted background network of molecular interactions. The algorithm is initialised by setting a 'working' subgraph G w . A node is randomly picked to subgraph G w with the check of improving the score. A simulated annealing process will output the highest-scoring component(s), which represents an active pathway/subnetwork of highly biological interest [40] . Compared to jActiveModules, gene expression network analysis (GXNA) [46] made several improvements in terms of scoring functions and algorithms. The algorithm primarily starts with a seed vertex and gradually expands around it by greedy search of maximal score node. The method has successfully been applied to retrieve several known and potential pathways related to cancer and immune system. Segal et al. [42] proposed a unified probabilistic model to identify differential pathways. It successfully discovered coherent functional groups and entire protein complexes from networks. They also developed a clustering method to group the functional gene modules related to 22 tumour types in gene co-expression networks [54] . Scott et al. [45] developed a computational method by colour coding to reconstruct signaling pathway from yeast protein interaction network. In their method, a number of possible pathways are firstly found with a score assigned to each candidate and the top scoring pathways are then assembled into a signaling subnetwork. NetSearch [41] aims to extract signal transduction pathways from protein interaction maps and gene expression profiles. The algorithm implements k-means algorithm firstly to group all genes into clusters according to their expression profiles, then a statistical score is assigned to each possible pathway. It ranks the candidate pathways and then aggregates top scoring pathways into a signalling pathway. Among the existing methods, some of them map the differential expression values to the network, while some of them combine various information in the scoring scheme. For instance, Bebek and Yang [47] developed an algorithm to reconstruct signal transduction pathway in reliable protein interaction networks. The protein interaction network is integrated with microarray expression profiles, protein subcellular localisation, and sequence information, which reduces the false positives. Given a pair of starting and ending proteins, the method is able to recover candidate pathway segments between these two proteins with possible missing linkages. Sohler et al. [43] presented two algorithms embedded in ToPNet to detect active pathways in analysing expression dataset. They used three different networks of experimentally determined interactions, transcriptional regulatory relations and a literature network. An algorithm of searching significant area was designed to detect subnetworks consisting of significantly regulated genes. The other algorithm was used to perform pathway queries for detecting networks including molecules that are not necessarily significantly regulated. Breitling et al. [44] developed a method to rank genes by their differential expression. They identified the active subnetworks by iteratively extending subset of gene which is initially from local-minimal node. Ulitsky and Shamir [50] proposed a confidence-based method for extraction of functionally coherent co-expressed modules in a weighted protein interaction network.
The above methods are heuristic algorithms to identify the dysfunctional pathways. Essentially, extracting responsive functional modules from a weighted network can be formulated as an optimiation model. Dittrich et al. [48] developed an optimisation framework to identify functional modules in a PPI network. The novelty of their method is that it can quickly extract optimal subnetworks. Specifically, a new score based on signal noise decomposition is proposed to weigh subnetworks. Then the problem of finding maximum weighted subnetworks is transformed into the well-known prize collecting Steiner tree problem, where a mathematical programming based algorithm is employed to solve it. We have also proposed computational methods to detect signaling pathways from a PPI network by integrating PPI information with microarray data [49, 51, 55] . We developed a novel integer linear programming method for uncovering signal transduction networks by connecting the starting node and ending node [49] . The subnetwork to be found is regarded as a connected subnetwork with maximum weights. Different from the heuristic methods, our optimisation model extracts a signal transduction network directly from a PPI network rather than first identifying possible linear paths and then assembling them into a signal transduction pathway. Besides, we also developed a method to identify a connected pathway in the network by a nonparametric statistical measure of differential expression level. Specifically, by using signal-to-noise ratio to measure the differentially expressed level of genes, the problem is formulated as a mixed integer linear programming problem [51] . We implemented this method to identify the differential pathways of breast cancer metastasis. Moreover, a quadratic programming model and a fast approximate algorithm were proposed in [55] to identify the condition specific subnetwork and applied to type-2 diabetes study.
The information of protein interactions usually gives an outline of their relationship, but the protein interactions are generally conditionally specific, for example, at a specific time and within a specific region, especially in the disease state. Therefore a good score scheme should consider a specific condition as accurate as possible. To study the dynamics of active pathways in different states, we proposed an edge-extension algorithm to identify the highscored significant pathways in the different development stages of AD [52] . The dynamical pathway as well as its biological implication during the disease progression was identified. In this work, the specific information of the protein interaction in the specific condition of the disease was considered with a new scoring scheme by Fisher's method.
The pathways of protein/gene interactions are the pipelines of the cell performing its functions. For evaluating these known pathways, the relationship or association between them and a disease also sheds light on their dysfunctions in complex diseases. Draghici et al. [56] conducted a pathway analysis that attempts to identify the most relevant pathways in a given experiment. In certain situations, they developed an impact analysis of the related pathways by combining gene differential expression, gene type and position in the given pathways and their interactions. They found the significant pathways in lung adenocarcinoma by ranking them with the impact scores. Saito et al. [57] proposed a probabilistic graphical model to estimate the consistency of a given network with the gene expression data. A network consistency probability of the likelihood corresponding to the measured data was estimated, which was used to bridge the network structure and gene expression measurements. This work sheds light on the network structure variations in terms of the dynamical changes in molecular interaction mechanisms that occur in response to the environment. We also developed a method to identify the relationship between AD-related pathways in different brain regions [58] , which adopts a ranking scheme to analyse the important dysfunctional crosstalk of pathways in six AD brain regions, and found several interesting crosstalking pathways.
Exploration of disease associations
Systems biology holds the dream to explore the underlying mechanisms of complex diseases, such as cancer, diabetes and AD. In the preceding sections, we reviewed the computational methods of identifying the disease genes and disease-responsive active pathways, which play crucial roles in bridging the gap between genotype and disease phenotype. In this section, we summarise recent works on analysis of disease classifications and associations based on molecular networks. Clearly, studying disease associations can provide valuable insights into identifying not only the disease genes but also the pathways or modules specifically in a certain disease, which in turn can be taken as the biomarker of complex disease. The basic idea is illustrated in Fig. 4a . The upper level shows the map of relationship between various diseases. The linkages of the disease genes/proteins and/or the active pathways/modules are represented in the lower level in Fig. 4a . Relationship between diseases shown in the upper level is important to gain insight into the aetiology and pathogenesis of similar diseases. The important features underlying the network in the lower level such as the hub genes and the functional modules, correspond to the specific disease states during the disease progression. These identified active pathways or functional modules can be directly used as network biomarkers or signatures to represent the diseases from the clinical perspective. Note that the traditional disease classification was mainly based on the observed correlation between pathological analysis and clinical syndromes, which has been widely recognised to have shortcomings on sensitivity and specificity [59] . In contrast, the networkbased approach provides a new perspective for the systemwide analysis on disease diagnosis, and the identified disease-responsive genes and modules can facilitate the development of better diagnostic markers and the discovery of core alterations for human complex diseases.
Often, a complex disease is believed to be caused not by individual genes, but rather by variations in a large number of correlated genes and their complex interactions. In Fig. 4a , when the upper level contains the phenotypes of disease and non-disease, the association study can be formulated as a disease classification. Chuang et al. [60] proposed a protein network-based approach that identifies subnetworks as the signatures of a disease, and classified metastatic against non-metastatic tumors. Instead of individual genes, they took advantage of the genes in these identified subnetworks from breast cancer patients to predict whether a breast cancer tumor is likely to spread. Given a particular subnetwork M, they defined a as its vector of activity scores over the tumor samples, c as the corresponding vector of class labels of metastatic or nonmetastatic. By implementing a Z-score transformation (similar to that described in the former section) to normalise expression values g ij to z ij , each gene i has mean m ¼ 0 and standard deviation s ¼ 1 over all sample j. They designated the subnetwork activity a j as a combined score of the n-member genes: a j = i z ij / n √ . The relationship between a and c was defined as
where p(x, y) is the joint probability density function of a ′ and c, p(x) and p( y) are the marginal probability density function of a ′ and c, respectively. a ′ is a discretised form of a, that is, activity levels are discretised into ⌊log 2 (no. of samples) + 1⌋ equally spaced bins. The particular subnetwork maximising S(M ) is regarded as optimal for classification. Then they performed a greedy algorithm to identify the candidate subnetworks to classify the samples. Their results were shown to be more accurate and reproducible than two sets of individual marker genes [60] . In the similar manner, Taylor et al. [61] provided a method to analyse the coordinated expression of 'hub' proteins and their interacting partners as a means of predicting breast cancer prognosis. They combined 79 human tissues transcriptomes together to average their Pearson correlation coefficient, and mapped the information to the protein interactions. Moreover, an affinity propagation method was used to derive hub-related modules in the protein networks. They developed a method to classify the disease and control patients by the modularity of hub and its interacting partners. These hubs and their related modules are represented as specific signatures of breast cancer [61] . In this topic, we also proposed an efficient method to define and further discover network biomarkers for prostate cancer by combining gene expression profiles, mass spectrometry and protein interactions [36] . The identified network biomarkers can accurately distinguish the prostate patients from the normal ones.
Expression-based classification is also a challenging problem in complex diseases because of factors such as cellular heterogeneity within a tissue sample and genetic heterogeneity across patients [59] . A promising technique is to incorporate pathway information in order to classify diseases based on the activity of entire signalling pathways or complexes rather than on the expression level of individual genes or proteins. Lee et al. [62] proposed a new disease classification method based on pathway activities inferred from each patient. A pathway activity level is summarised from the gene expression levels of its condition responsive genes, defined as the subset of genes in the pathway whose combined expression delivers optimal discriminative power for the disease phenotype. Their method achieved better performance than classifiers based on individual gene expression in classifying complex diseases such as cancers. Suthram et al. [63] presented a quantitative framework to identify the disease relationships by comparing and contrasting diseases in an integrated network from disease related microarray information and human protein interactions. They clustered functional modules in a protein interaction network and calculated their response scores in 54 diseases. The correlations between diseases were identified through these dysfunctional modules. The common disease state signatures of these modules as well as the specific disease features were also identified and categorised. The shared pathophysiology and pathological pathways were identified by the disease relationships.
The associations among diseases are often identified by the relationship among disease pathways. For instance, the subnetworks of these disease pathways are used as the network biomarkers of specific diseases. The common and difference of the diseases are used to construct the relationship based on the metabolic network differences, protein network similarity and the related gene sets. Goh et al. [64] built a human diseasome. From the human disease network and disease -gene associations, they found that essential human genes were likely to encode hub proteins and were expressed widely in most tissues. However, the majority of disease genes were shown to be non-essential and were localised in the functional periphery of the network. Lee et al. [65] built a human metabolic network and related it to the human diseases. They constructed a bipartite human disease association network and found that the connected disease pairs display a higher correlated reaction flux rate, corresponding enzyme encoding gene co-expression, and higher comorbidity than those that have no metabolic link between them. On the other hand, the topology-based analysis can provide an alternative explanation for disease comorbidity of human diseases. For instance, the topological structure and function of the human metabolic networks can provide insight into disease diagnosis and prevention. Limviphuvadh et al. [66] investigated the similar domain signatures in six neuron diseases by employing PPI networks. The common domain characteristics were identified in these neuron induced diseases indicating common molecular pathogenic mechanisms. Hu and Li [67] proposed a general framework to associate diseases by networking pathways and delineated the relationship between any two or even more disease phenotypes at the molecular pathway/pathway interaction level. They demonstrated that the method can both identify signature pathways for each disease and establish a valid association of two diseases of obesity and diabetes. Ray et al. [68] and Miller et al. [69] proposed a similar analysis of the relationship between AD and cardiovascular disease and between AD and ageing individually by gene co-expression networks. They built gene co-expression networks in the diseases and identified the responsive modules. The similarities and differences of the functional modules in these diseases provided further evidences to link AD and cardiovascular disease and that of AD and ageing. We also developed a method to study the relationship between ageing and other kinds of diseases [70] , where a human disease-ageing network was constructed by integrating human PPIs, disease -gene associations, ageing -gene associations and physiological system-based genetic disease classification information. The human disease genes were identified to be much closer to ageing genes than expected by chance. According to their relationships with ageing, we categorised diseases into two types and analysed the intricate relationship between the ageing process and genetic diseases. All research works above show that the network-based study provides not only evidence for the relationship among diseases, but also biological implications for prying into the nature of human diseases.
Drug targets and drug combinations
Complex diseases need complex therapeutic approaches. Generally, many diseases result from multiple genetic and environmental factors, and cause severe dysfunction of some cellular components. To restore the individuals with complex diseases, agents that can intervene different disease factors simultaneously are highly demanded [10] . Traditional one-target one-drug paradigm that has been the dominating drug discovery approach is hard to handle multi-factors and leads to many marketed drugs unable to treat certain complex diseases sufficiently [71] . Genomewide massive data and sources provided new opportunity to facilitate pharmaceutical research [72] . Fig. 4b shows a simple example of drug and its target network, which is a blueprint to identify drug targets and drug combinations by the network-based method.
Specifically, network-based systems biology techniques can offer a novel alternative for drug discovery through the development of models which can place drug targets in their physiological context indicating a global consideration of environment with their key molecular interactions [73, 74] . Among several analyses of drug targeting network, Yildirim et al. [75] built a bipartite graph composed of approved drugs and proteins linked by drug target binary associations. Their resulting network connects most drugs into a highly interlinked giant component, with strong local clustering of drugs of similar types. To analyse the relationships among drug targets and disease gene products, they measured the shortest distance between both sets of proteins in current models of the human interactome network. Significant differences in distance were found between aetiological and palliative drugs. On the other hand, Yamanishi et al. [76] developed statistical methods to predict drug -target interaction networks from chemical structure and genomic sequence information simultaneously. They characterised four classes of drugtarget interaction networks and formulated the drug -target interaction inference as a supervised learning problem for a bipartite drug -target graph. Nacher and Schwartz [77] compiled a drug -therapy network defined by known relationships between drugs and their therapeutic applications. They analysed the bipartite network of therapies and drugs, the network of therapies and the network of these drugs. All those works above based on properties of the networks/subnetworks provided new insights into possible strategies for future drug development for complex diseases.
Drug targets have traditionally been predicted on the basis of molecular or cellular features of proteins. By a networkbased strategy, we have proposed a novel exact and efficient method to detect drug targets in a metabolic network [78] . The problem is defined to find a set of enzymes whose inhibition stops the production of a given set of target compounds and meanwhile minimally eliminates non-target compounds in the context. We formulated the minimum side-effect drug target detection problem as an integer linear programming model, which ensures that an optimal solution can be found efficiently without any heuristic manipulations. It can be applied to large-scale networks including the whole metabolic networks for most organisms. As to the consideration of the side effects, Campillos et al. [79] proposed a detailed analysis of the side-effect profiles of almost 800 marketed drugs. Instead of exploiting similarity in chemical structure or in activity across cell lines, they used phenotypic sideeffect similarities to infer whether two drugs share a target. After building a network of 1018 side effect-driven drug -drug relations, several validated drug-target interactions were identified and some were confirmed in cell assays. Atias and Sharan [80] present an approach to predict the side effects of a given drug. Their method combined correlation-based analysis with network-based diffusion to predict the side effects of drugs and achieved high retrieval accuracy. The method has the potential applications in drug target identification.
Network models have provided evidences for the complexity of the dysfunction of complex diseases, and also opened a new era for drug discovery mainly from computational tools, in particular for cocktail drug discovery [81] . Inhibition of several targets simultaneously could be more efficient than the complete inhibition of one target [82] . Multi-targets and combinatorial therapies lead us to a novel drug discovery strategy based on the network approaches. Lehar et al. [83] proposed a drug combination strategy to show that the promise of synergistic drug combinations is generally more specific to particular cellular contexts than single-agent activities by using large-scale simulations of bacterial metabolism and multi-dose experiments relevant to diverse diseases. Vazquez [84] introduced a method to uncover drug combinations with a putative effective response when presented to a heterogeneous population of malignant agents, such as cancer cell lines or viruses. They built a drug-response network and used an associated minimal hitting set method to identify effective drug combinations. We also presented a network-based approach to identify effective drug combinations to type-2 diabetes [81] . The basic assumption is that a subnetwork or pathway will be affected in cellular systems after a drug is administrated. We defined a score to evaluate the overall effect of one drug by taking into account both efficacy and side-effects. The affected subnetwork thereby was implemented to identify effective drug combinations by comparing the subnetworks of individual drugs with that by the combination drugs. Based on the test on FDA approved type-2 diabetes drugs, we identified several high-scored combinations, including the combination of Metformin and Rosiglitazone which is actually called Avandamet, a drug that has been successfully used to clinically treat for type-2 diabetes, thereby confirming the effectiveness of our method [81] .
Discussion and conclusion
A complex disease, such as cancer, diabetes and AD, is a disease on the system, or a disease of the molecular network. Although the network-based medicine is in its beginning and developing period, the outlines and achievements described in this paper demonstrate its effectiveness and power to address the missions. For instance, network-based studies not only enable us to address complex dysfunctional processes with clinical implications, but also elucidate how the dynamical behaviour and function of signaling networks contribute to the process of disease development and progression at a systems level. On the other hand, for drug discovery and treatment, network-based approaches have shown to be a new powerful analytical tool to provide reliable alternative to drug targeting and designing, in particular to the cocktail drug design.
In this paper, we firstly introduced the main features and advantages of various types of biomolecular networks for studying complex diseases. Then we summarised the recent progress in analysing complex diseases by network-based approaches. The review included a variety of levels of networks from genes, proteins, metabolites, to pathways and drug-target networks and was organised into four parts, that is, identifying disease genes, disease-responsive active pathways, disease classifications and associations and drug targets and drug combinations. Through summarising the existing works, we showed that network-based analysis on complex diseases holds great potential for deciphering disease mechanism, which is in turn able to accelerate the advance of disease diagnose, prevention and even novel therapy.
Network-based systems biology is increasingly attracting much attention from communities of both experimental and computational biologists, and is expected to revolutionise our understanding of cellular systems as a whole. The methodologies and techniques of systems biology have been applied for analysing the molecular mechanisms of complex diseases and provided new solutions for preventing and curing the diseases [85] . In this paper, we described various methods of identifying disease genes and dysfunctional pathways which focus on different diseases by different datasets with self-reported performances and specific methodological features. However, it is an interesting and challenging task to compare them and make assessments on benchmarks. Although most of those methods are not designed for one particular disease, that is, the network-based methods to prioritise cancer genes can also be applied to predict diabetes genes in the same way, considering that the disease-specific knowledge in the identification will improve the efficiency and accuracy [86] . Those disease-responsive genes and pathways will also be crucial for linking with the disease-specific phenotypes. The network biomarkers of a specific disease play important roles in disease classification and disease relationship. They are also key concerns in the network-based drug discovery and design. The generality of these methods and the specificity of these results indicate the potential and the ability of further extension of network biology, which is also a future topic in the complex disease study.
The availability of massive data by various novel highthroughput technologies such as next-generation sequencing, expression quantitative trait loci and proteinbinding microarray would provide more valuable information to study complex diseases [7] . Time-and tissue-specific gene expressions and PPIs data allow us to implement analysis on the spatio-temporal dynamics of pathogen and disease progression processes. The structure and dynamics of protein signalling networks are also crucial to cell decision processes and the formation of tissue boundaries. In fact, complex diseases such as cancer and diabetes can be viewed as diseases of such dynamic networks [9] . Hence, elucidating the dynamics underlying molecular networks of different levels will facilitate the discovery of disease mechanisms and the finding of ways to attack the dysfunctions, which is a future research topic.
Another research direction is to develop methodologies to reconstruct the network by integrating the heterogenous high-throughput data so as to implement the analysis of complex diseases. Different experimental technologies assess various aspects of a complex system with different depth and breadth. These data at different levels from gene, RNA, protein and metabolite will provide more information for measuring the systems in a more comprehensive and accurate manner. Integrating the datasets generated by diverse approaches also leads to meaningful and accurate interpretation of complex diseases [87, 88] . It is a promising research direction to develop data integration methods that can handle multiple data sets differing in statistical power, type, size and network coverage [89] . However, the heterogeneous data need to be integrated carefully because of their complex nature when we use them in the complex disease research. At the same time, network comparison techniques are able to provide more evidences for the consistency and specificity of networks from different levels of one species and from different species [90] . Developing network comparison and queries techniques will also sharpen our tools in analysing complex diseases [91] .
It is known that the epigenetic and environmental effects are crucial in the mechanisms of complex diseases, such as diabetes which is highly correlated with the lifestyles [92, 93] . The network-based method has indicated that obesity is also clustered in communities, that is, if one person became obese during a given time interval, his friend's chances of following suit increased significantly [94] . DNA methylation and histone modification are predominating in epigenetics and they play important roles in maintaining stem cell pluripotency and in cancer pathogenesis [95] . Integration of these important resources in network analysis will provide accurate explanation for the complex cellular and molecular disease systems.
With vast amounts of omics data generated, the challenge now is to develop robust methods to interpret these data.
Once the sophisticated methods are available, an important direction is to apply these network-based approaches into disease diagnosis and treatment. From clinical perspective, application of network biomarkers or network signatures holds the promise to revolutionise the medicine technology. A number of studies have shown the compelling power of network analysis in considering the multi-target strategies over single-target drug design approaches [71, 96] . Although there are still many hurdles to directly bring the predicted drug targets and network-based drugs into the clinic, we believe that the network-based methods will eventually revolutionise our view of fundamental biological process as well as disease progression and innovate the disease diagnose and drug discovery.
